Aztreonam

Aztreonam is a synthetic monocyclic beta-lactam antibiotic, which has a very high affinity for penicillin-binding protein 3 (PBP-3) . (In Vitro) :Aztreonam (SQ-26,776) is a synthetic monocyclic beta-lactam antibiotic (a monobactam), with the nucleus based on a simpler monobactam isolated from Chromobacterium violaceum. It was approved by the U.S. Food and Drug Administration in 1986. It is resistant to some beta-lactamases, but is inactivated by extended-spectrum beta-lactamases. Aztreonam has no useful activity against gram-positive or anaerobic microorganisms. Aztreonam (SQ-26) is similar in action to penicillin. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidogly can crosslinking. It has a very high affinity for penicillin-binding protein 3 (PBP-3) and mild affinity for PBP-1a. Aztreonam (SQ-26) binds the penicillin-binding proteins of gram-positive and anaerobic bacteria very poorly and is largely ineffective against them. Aztreonam (SQ-26) is bactericidal but less so than some of the cephalosporins.

78110-38-0

SQ 26,776

Pharmacology & Drug Discovery

>98% (HPLC)

Water: 11 mg/mL (25.26 mM) ; DMSO: 87 mg/mL (199.8 mM)

CC1C (C (=O) N1S (=O) (=O) O) NC (=O) C (=NOC (C) (C) C (=O) O) C2=CSC (=N2) N

C13H17N5O8S2

435.43

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.